Full Text
RWD6 Costs of Dose Escalation Among Patients with Inflammatory Bowel Disease Treated with Vedolizumab and Ustekinumab in Portugal

Abstract

Authors

J.P. Lopes da Cruz M. Faria A.S. Aleixo F. Pereira

Back to Volume 26, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×